▲ 0.00%
prev close
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-07-10 | OGNOrganon & Co. | Sell | $1,001 - $15,000 | 191d ago | — |
2025-07-10
Gary Peters
OGN
Amount
$1,001 - $15,000
Filed
191d ago
Recent News
Powered by Polygon.io
Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático
Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders
Trade Timeline
Congressional activity, newest first
Gary Peters
2025-07-10 · Sale
$1,001 - $15,000